LY03017 vs Remlifanserin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Serotonin 5-HT2A receptor (antagonist / inverse agonist) · full Alzheimer's Disease pipeline

LY03017

Developed by Luye Pharma Group

Phase 1 in Alzheimer's Diseasesmall molecule
Weak signal

NCT06388551 · Phase 1 · status unknown

This early-phase study randomly assigned healthy volunteers to ascending single oral doses of LY03017 or matching placebo under quadruple-blind conditions, tracking adverse events as the primary outcome. No results have been posted, so it remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known. Its registered primary outcome on ClinicalTrials.gov is "Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Remlifanserin

Developed by Acadia Pharmaceuticals

Phase 3 in Alzheimer's Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2028 · NCT06159673 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLY03017Remlifanserin
CDR-SB, change—Not reported—Trial running · NCT06159673
ADAS-Cog11, change—Not reported—Trial running · NCT06159673
ADCS-ADL, change—Not reported—Trial running · NCT06159673
MMSE, change—Not reported—Trial running · NCT06159673
Amyloid PET, change (centiloids)—Not reported—Trial running · NCT06159673

CDR-SB, change

LY03017
—Not reported
Remlifanserin
—Trial running · NCT06159673

ADAS-Cog11, change

LY03017
—Not reported
Remlifanserin
—Trial running · NCT06159673

ADCS-ADL, change

LY03017
—Not reported
Remlifanserin
—Trial running · NCT06159673

MMSE, change

LY03017
—Not reported
Remlifanserin
—Trial running · NCT06159673

Amyloid PET, change (centiloids)

LY03017
—Not reported
Remlifanserin
—Trial running · NCT06159673
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

LY03017: no structured comparison results are available for Alzheimer's Disease.

Remlifanserin: no structured comparison results are available for Alzheimer's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY03017's landscape · Remlifanserin's landscape